(ALXO) Alx Oncology Holdings - Ratings and Ratios

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company that is aggressively pursuing innovative cancer therapies in the United States. The companys lead product candidate, Evorpacept, is a CD47 blocking therapeutic biologic being developed as a combination therapy with other anti-cancer agents. Evorpacept has shown promise in various clinical trials, including Phase 2 studies for Gastric/GEJ cancer and head and neck squamous cell carcinoma, as well as Phase 1 studies for urothelial cancer.

The companys strategic collaborations with prominent pharmaceutical companies and research institutions, such as Jazz Pharmaceuticals, Quantum Leap Healthcare, MD Anderson Cancer Center, Sanofi, and University of Pittsburgh, underscore its commitment to advancing Evorpacept and other potential therapies. These partnerships are focused on exploring Evorpacepts potential in combination with various anti-cancer agents, including zanidatamab, fam-trastuzumab deruxtecan-nxki, rituximab, lenalidomide, isatuximab, and pembrolizumab, across a range of cancer types.

In addition to Evorpacept, ALX Oncology is also developing ALTA-002, a potent immune activator targeted to myeloid cells in the tumor, through its collaboration with Tallac Therapeutics, Inc. The companys robust pipeline and collaborations are supported by its license agreements with prestigious institutions, including the Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc.

From a technical analysis perspective, ALXOs stock price has been trending downward, with a current price of $0.48, below its 50-day and 200-day moving averages. The Average True Range (ATR) of 0.05 indicates a relatively low volatility, but the stock is still trading near its 52-week low of $0.41. Given the companys promising pipeline and collaborations, a potential catalyst for growth could be successful trial results or regulatory approvals. If Evorpacept demonstrates efficacy in its ongoing trials, we could see a significant increase in the stock price, potentially targeting the $1.00-$2.00 range in the short term, representing a 100%-300% increase from current levels.

Fundamentally, ALX Oncologys market capitalization is approximately $23.05 million, with no P/E ratio due to the companys current lack of profitability. The companys return on equity is negative, reflecting its significant investment in research and development. However, if Evorpacept or other pipeline candidates demonstrate success, the companys valuation could increase substantially. Based on the current data, a forecast for ALXOs stock price would depend on the outcome of its ongoing clinical trials and the success of its collaborations. If the trials yield positive results, we could see a significant upward revision in the stock price, potentially driven by increased investor confidence and a revaluation of the companys potential.